Oral bacteria can spread through the body and have been associated with a variety of systemic diseases [1]. Thus, a report from Segata et al. [2] in Genome Biology found that oral cavity and stool bacteria overlapped in nearly half (45%) of the subjects in the Human Microbiome Project. Transfer of oral bacteria to the gut is therefore common. Members of the oral and oropharyngeal microbiota reach the stomach through swallowed saliva, nutrients, and drinks. Saliva production ranges from 0.75 to 1.5 L/day [3], but various stages of the disease can affect the production. The ingested saliva contains an enormous amount of oral bacteria. In general, these bacteria are poor colonizers of the healthy intestine [4]. In severe diseases, however, increased amounts of oral bacteria have been reported in the intestine, e.g. in inflammatory bowel disease, HIV infection, liver cirrhosis, colon cancer, primary sclerosing cholangitis, gastroesophageal reflux disease, and alcoholism (for a review see Atarashi et al. [5]). In patients with periodontitis, \(10^5\) to \(10^{10}\) of the keystone periodontal pathogen Porphyromonas gingivalis can be swallowed each day [6,7]. If oral bacteria can tolerate the harsh pH of the stomach, they may reside and proliferate in the gastrointestinal tract [8]. This is particularly the case with P. gingivalis, which is acid-resistant and may migrate to the colon and change colonic functions [8,9] (Figure 1). In support of this, P. gingivalis is thought to have a role in orodigestive cancers [10].

P. gingivalis is a great manipulator of the oral microbiome and immune defense [11–14] and diseases related to periodontitis. It is often associated with dysbiosis in the gut microbiota [15–17]. The present Note discusses if oral bacteria, particularly P. gingivalis, can modulate the microbiome of the gut in animals and humans.

Disturbances in the gut microbiota by swallowed bacteria may lead to endotoxemia causing metabolic disorders (Figure 2). To test this, P. gingivalis was administered orally (2 times a week for 5 weeks) to mice (C57BL/6N). This caused increased levels of plasma endotoxin and insulin and reduced mRNA expression of the tight junction protein ZO-1 in the small intestine. Pyrosequencing showed that Bacteroidales was significantly increased [18]. P. gingivalis was not detected in the blood of the P. gingivalis-administered mice, but other bacterial DNA was found here. It was speculated that the endotoxemia was not necessarily induced by bacteria from the oral cavity but could be related to changes in the gut microbiota caused by oral bacteria that had been swallowed. If these results are confirmed, they suggest a new paradigm for the relationship between periodontitis and systemic diseases.

In another study with C57BL/6N mice, a single administration of P. gingivalis changed the gut microbiota significantly compared to sham-treated mice, with increased Bacteroidetes and decreased Firmicutes [11]. The mRNA expression of the tight junction proteins Tjp1 and Ocln, involved in intestinal permeability, was downregulated. Also, these changes were thought to be due to increases of endotoxin in the blood since there was no outgrowth of P. gingivalis in the gut. Disturbance in the composition of the gut microbiota occurred even
after a single administration of *P. gingivalis*, linking periodontitis and systemic disease. The amount of *Porphyromonadaceae* in the fecal samples was less than 0.003%. This agreed with findings from another mouse model where *P. gingivalis* acted as a keystone pathogen in periodontitis disrupting host-microbial homeostasis when present at <0.01% of the total microbiota [19].

In 10 C57BL/6J mice, tooth ligatures imbibed with *P. gingivalis* were inserted to induce periodontitis, while 10 mice were sham-ligated [20]. 16S rRNA pyrosequencing detected no significant differences in the main phyla and in the genus *Parabacteroides* in the gut of the two groups, but the experimental group displayed significant alveolar bone loss. The ileum of the *P. gingivalis* group showed significantly upregulated occludin, claudin2, and NOD2. This suggested that periodontal inflammation, to some extent, had affected the mechanical and immune barrier functions of the mouse gut.

In a mouse (DBA/1J) experimental rheumatoid arthritis (RA) model, *P. gingivalis* was orally administered, intended to mimic periodontitis patients swallowing the bacterium. The gut microbiome changed, followed by increased serum endotoxin and inflammatory markers, and the gut barrier function was impaired [9]. A clear relationship between the oral and gut microbiota and RA was demonstrated. Thereafter, DBA/1J mice were given orally *P. gingivalis* and *Prevotella intermedia*, which contrary to *P. gingivalis* has no peptidyl arginine deiminase causing citrullination. This was followed by induction of collagen-induced arthritis (CIA). A significant change in the gut microbiome occurred [9]. *P. gingivalis* but not *P. intermedia* significantly increased IL-17 levels in sera and culture supernatants, as well as the Th17 cell proportions among mesenteric lymphocytes and Peyer’s patches. Although *P. gingivalis* aggravated CIA in the DBA/1J mice, it did not further increase the level of anti-citrullinated protein antibody. The suspected role of *P. gingivalis* in RA could, therefore, be by affecting the gut immune system and by causing composition shifts in the gut microbiota rather than by citrullination of proteins.

Periodontitis may affect non-alcoholic fatty liver disease (NAFLD) [18,21], the most common form of chronic liver disease. In addition, the gut microbiota has been suggested to mediate the development and progression of NAFLD [22–24]. C57BL/6J mice (8 weeks old) were given the periodontopathogen *Aggregatibacter actinomycetemcomitans* or saline for 6 weeks and either normal chow (NCAa, NCco) or high-fat diet (HFaa and HFco) [25]. The NCAa and HFaa groups represented mice with weakened glucose tolerance and insulin resistance compared to
controls. Higher hepatic steatosis was detected in the HFAa mice than in the HFco animals after ingestion of *A. actinomycetemcomitans*, which affected NAFLD by changing the composition of the gut microbiota and glucose metabolism.

Infection with type II *P. gingivalis* in an NAFLD mouse model accelerated dramatically the progression of NAFLD [21], which was considerably faster than in control mice on a high-fat diet (HFD), but not those on a basal diet. HFD and *P. gingivalis* cooperatively increased the risk of NAFLD in this mouse model. Infection with other oral bacteria (Streptococcus sanguinis and *S. salivarius*) did not accelerate the progression of NAFLD, which might be due to a specific *P. gingivalis* effect under HFD conditions. The results should be interpreted with caution because the bacteria were administered via the jugular vein, not by the oral cavity. Furthermore, the control bacteria used in this study were inappropriate; future studies should use Gram-positive rods as controls for the test species (*P. gingivalis*) rather than Gram-positive cocci.

The effect of oral bacteria on the gut microbiota has also been studied in man. Several of these studies support findings from animal models. Thus, in patients with liver cirrhosis, a major change in the gut microbiota was due to the massive invasion of the gut by oral bacteria [26]. More than half (54%) of the patient-enriched, taxonomically assigned bacterial species were of oral origin (mostly veillonella and streptococci). This suggested that an invasion with mouth bacteria to the gut had taken place in the patients with liver cirrhosis. The correlation of the severity of liver cirrhosis with an abundance of the invading bacteria further indicated that oral bacteria other than *P. gingivalis* could also play a role in the pathology of liver cirrhosis.

*P. gingivalis* has been associated with NAFLD and non-alcoholic steatohepatitis (NASH) [21]. When *P. gingivalis* was examined from 150 biopsy-proven NAFLD patients (102 with non-alcoholic steatohepatitis, 48 with non-alcoholic fatty liver (NAFL), and 60 non-FADL control subjects), it was detected in the gut of the NAFLD patients at significantly higher levels than in non-NAFLD controls (46.7% vs 21.7%, odds ratio 3.16). This supported experiments in mice already mentioned [21]. Altogether, these animal and human studies indicate a clear association between *P. gingivalis* and NAFLD. Also in NASH, the more advanced stage of NAFLD, the detection frequency of *P. gingivalis* was higher than in non-NAFLD subjects (52.9%, odds ratio 3.91).

Komazaki et al. [25] examined the relationship between periodontitis and clinical/biochemical parameters in 52 NAFLD patients. IgG antibody titers were measured against *A. actinomycetemcomitans*, *P. gingivalis*, and *Fusobacterium nucleatum*. Only anti-*A. actinomycetemcomitans* antibody titers correlated positively with visceral fat, fasting plasma insulin and HOMA-IR (Homeostatic Model Assessment for Insulin Resistance), and negatively with the liver/spleen ratio.

When metagenomic shotgun sequencing and a metagenome-wide association study were made with dental, salivary, and fecal samples from a cohort of RA patients and healthy controls, concordance was detected between the oral and gut microbiomes. This suggested an overlap in the prevalence and function of bacterial species in the two body sites [27]. Alteration in the proportion of species was seen both in the oral and gut microbiota of the RA patients but was partially resolved after treatment of RA. The authors suggested that RA could represent a state of chronic inflammation that may be provoked or aggravated by the overgrowth of pathogenic bacteria or by the lack of immune modulating commensal bacteria.

In another study sequencing libraries of 16S rDNA were used to compare the subgingival biofilm and intestinal microbiota in patients (*n* = 40) with chronic periodontitis and metabolic syndrome, and healthy individuals (*n* = 40). *P. gingivalis*, *Tannerella forsythia*, and *Treponema denticola* appeared in high concentrations in the subgingival microbiota while the intestinal microbiome was dominated by *Enterobacteriaceae* and *Eubacteriaceae*. There were signs of intestinal dysbiosis, mostly related to a decrease of protective species [28]. Whether the oral bacteria were related to the intestinal dysbiosis was not examined.

Lourenço et al. [17] defined the gut microbiota in individuals with periodontal diseases. They found that individuals with periodontal diseases (gingivitis *n* = 14, “chronic” periodontitis *n* = 23), in contrast to animal models [11,18], had a less diverse intestinal microbiome. The gut microbiota was characterized by an increase in the Firmicutes/Bacteroides ratio and enrichment in Euryarcheota, Verrucomicrobiota, and Proteobacteria. Besides, high numbers of a large variety of oral taxa were associated with periodontal destruction and inflammation in the gut irrespective of the periodontal status. Several of them were genera of putative periodontal pathogens. How the oral microbiota survived in the mucosal barrier of the gut or circumvented it to establish an infection there was not considered.

The large amounts of swallowed dead bacteria from the mouth may stimulate several pathogens in the gut (necroptrophy) and create a new phenotype by upregulation of bacterial virulence genes (necrovirulence) and increased cytotoxicity. This has been demonstrated for periodontopathogens *in vitro* [29]. Cultures of *P. gingivalis* and *P. intermedia* exhibited a significant increase in growth when at least 10 dead bacterial cells were at disposal for one living cell. The
growth of *P. intermedia* was stimulated much less by *Streptococcus oralis* and *Streptococcus gordonii* than by dead *P. gingivalis* and *P. intermedia*. Furthermore, gingipain virulence genes of *P. gingivalis* such as *rgpA*, *rgpB*, and *kgp* were upregulated in presence of dead *P. intermedia*. The long fimbriae gene *fimA* and the collagenase *prtC* gene were also upregulated.

There is an increasing amount of evidence suggesting that certain oral bacteria can contribute to oral and gastrointestinal cancers [10,30]. For example, *P. gingivalis* can be implicated in precancerous gastric and colon cancer lesions. Epidemiological studies have shown that there is an increased risk for such cancers in both men and women with periodontal disease or tooth loss [10]. *P. gingivalis* up-regulates specific receptors on oral squamous cell carcinoma cells and keratinocytes, induces epithelial-to-mesenchymal transition of oral epithelial cells, and activates metalloproteinase-9 and interleukin-8 in cultures of carcinoma cells. In addition, *P. gingivalis* accelerates cell cycling and suppresses apoptosis in cultures of oral epithelial cells [10]. There may be a direct relationship between *P. gingivalis* and oro-digestive cancers, where the contribution to carcinogenesis may be due to the secondary intrusion of the oral bacterium outside of its primary location (oral cavity), yet still within anatomically continuous regions.

Association of oral bacteria with gastrointestinal cancer was also demonstrated by Flemer et al. [31] who profiled the microbiota in oral swabs and stools of patients with colorectal cancer (CRC) and control subjects by 16S rRNA gene sequencing. They found that several operational taxonomic units (OTUs) were shared between oral swabs and stool samples that may be potential tools for the detection of CRC. Some of these OTUs corresponded to late colonizers of oral biofilms such as *F. nucleatum*, *Parvimonas micra*, and *Peptostreptococcus stomatitis*. The oral microbiota in colorectal cancer was distinctive and predictive. Association of oral *F. nucleatum* with CRC was further confirmed by the isolation of an identical clone of *F. nucleatum* from the oral cavity and tissue specimens of CRC in the same subjects [32].

The effect of oral bacteria on the gut microbiota has also been demonstrated through favorable changes after periodontal therapy [33]. Thus, periodontal treatment in cirrhosis was associated with improvement in oral and gut dysbiosis, systemic inflammation, Model for End-Stage Liver Disease (MELD) score and cognitive function. The improvement was especially seen in patients with hepatic encephalopathy. Furthermore, non-surgical periodontal treatment for 3 months of 10 NAFLD patients reduced the serum levels of AST and ALT, which are sensitive indicators of liver damage or injury. Periodontal treatment may, therefore, be an efficient supportive measure in patients with NAFLD [21].

**Concluding remarks**

The oral microbiome may have a great effect on the health of the gastrointestinal system. This has been reported in dental and medical journals of high impact. Both animal and human studies indicate that for example, *P. gingivalis* may influence the gut microbiota causing dysbiosis. This can happen despite the fact that the digestive tract hosts a much greater bacterial density than the oral cavity. Particularly long-term, orally ingested *P. gingivalis*, as seen in periodontitis, may affect intestinal dysbiosis. Also, the periodontopathogen *A. actinomycetemcomitans* may alter the gut microbiota but *P. gingivalis* and *A. actinomycetemcomitans* are not the only periodontopathogens that can translocate to extraoral sites. Actually, a large variety of oral species can reach the intestinal microbiota through swallowing, regardless of the periodontal status, but only a subset of these bacteria seems to colonize the gut when the microbiota here is dysbiotic. Whether this colonization requires a dysbiotic oral microbiota is not clear, but cannot be excluded. Anyhow, severe diseases and genetic susceptibility of the host may promote ectopic colonization of oral bacteria. Good oral hygiene, periodontal therapy, prebiotics, and probiotics may help ameliorating oral bacteria-elicited gastrointestinal disorders. The intestinal link may also be another pathway for oral bacteria to cause systemic inflammatory diseases. However, this area of research is still in its infancy and requires further investigation before firm conclusions can be drawn.

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**Funding**

This work was supported by JSPS KAKENHI Grant number [18H04067] (to K.Y.).

**References**

[1] Olsen I. From the acta prize lecture 2014: the periodontal-systemic connection seen from a microbiological stand point. Acta Odontol Scand. 2015;73(8):563–568.

[2] Segata N, Haake SK, Mannon P, et al. Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples. Genome Biol. 2012;13(6):R42.

[3] Edgar M, Dawes C, O’Mullane D. Saliva and oral health. 3rd ed. London: British Dental Association; 2004.

[4] Seedorf H, Griffin NW, Ridaura VK, et al. Bacteria from diverse habitats colonize and compete in the mouse gut. Cell. 2014;159(2):253–266.
Porphyromonas gingivalis through modulation of the gut microbiota and gut immune system. Sci Rep. 2017;7(1):6955.

[10] Olsen I, Yilmaz Ö. Possible role of Porphyromonas gingivalis in orodigestive cancers. J Oral Microbiol. 2018;11:1563410.

[11] Nakajima M, Arimatsu K, Kato T, et al. Oral administration of P. gingivalis induces dysbiosis of gut microbiota and impaired barrier function leading to dissemination of enterobacteria to the liver. PLoS One. 2015;10(7):e0134234.

[12] Maekawa T, Krauss JL, Abe T, et al. Porphyromonas gingivalis manipulates complement and TLR signaling in orodigestive cancers. J Oral Microbiol. 2011;46(2):235–239.

[13] Zenobia C, Hajishengallis G. Virulence factors involved in subversion of leukocytes and partly normalized after treatment. Nat Rev Genet. 2015;21(8):895–905.

[14] Olsen I, Hajishengallis G. Major neutrophil functions subverted by Porphyromonas gingivalis. J Oral Microbiol. 2016;8:30936.

[15] Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet. 2012;13(4):260–270.

[16] Fukuda S, Ohno H. Gut microbiome and metabolic diseases. Semin Immunopathol. 2014;36(1):103–114.

[17] Lourenço TGB, Spencer SJ, Alm EJ, et al. Defining the gut microbiota in individuals with periodontal diseases: an exploratory study. J Oral Microbiol. 2018;10(1):1487741.

[18] Arimatsu K, Yamada H, Miyazawa H, et al. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. Sci Rep. 2014;4:4828.

[19] Hajishengallis G, Liang S, Payne MA, et al. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbe and complement. Cell Host Microbe. 2011;10 (5):497–506.

[20] Meilian X, Ting Y, Ying Z, et al. Periodontal inflammation affects the mechanical and immune barrier functions of mice gut. Hua Xi Kou Qiang Yi Xue Za Zhi. 2016;34(4):414–418. (Article in Chinese, abstract in English).

[21] Yoneđa M, Naka S, Nakano K, et al. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. BMC Gastroenterol. 2012;12:16.

[22] Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7(12):691–701.

[23] Jiang W, Wu N, Wang X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015;5:8096.

[24] Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut. 2016;65(12):2035–2044.

[25] Komazaki R, Katagiri S, Takahashi H, et al. Periodontal pathogenic bacteria, Aggregatibacter actinomycetemcomitans affect non-alcoholic fatty liver disease by altering gut microbiota and glucose metabolism. Sci Rep. 2017;7(1):13950. Erratum in: Sci Rep. 2018; 8(1):4620.

[26] Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513 (7516):59–64.

[27] Zhang X, Zhang D, Jia H, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med. 2015;21(8):895–905.

[28] Petrukhina NB, Zorina OA, Shikh EV, et al. Microbiogenesis of subgingival biofilm and intestinal content in chronic periodontal disease in patients with metabolic syndrome. Stomatologija (Mosk). 2017;96 (4):11–19. (Article in Russian, abstract available in Russian from the publisher).

[29] Rodriguez Herrero E, Boon N, Pauwels M, et al. Necrotrophic growth of periodontopathogens is a novel virulence factor in oral biofilms. Sci Rep. 2017;7(1):1107.

[30] Ahn J, Chen CY, Hayes RB. Oral microbiome and oral and gastrointestinal cancer risk. Cancer Causes Control. 2012;23(3):399–404.

[31] Flemer B, Warren RD, Barrett MP, et al. The oral microbiota in colorectal cancer is distinctive and predictive. Gut. 2018;67(8):1454–1463.

[32] Komiya Y, Shimomura Y, Higurashi T, et al. Patients with colorectal cancer have identical strains of Fusobacterium nucleatum in their colorectal cancer and oral cavity. Gut. 2018; pii:gtj101–2018–316661.

[33] Bajaj JS, Matin P, White MB, et al. Periodontal therapy favorably modulates the oral-gut-hepatic axis in cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2018.